UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________. COMMISSION FILE NUMBER: 000-19271 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware ...

Business Segments - IDEXX operates through three primary business segments: Companion Animal Group, Water Quality Products, and Livestock, Poultry, and Dairy[16]. - The Companion Animal Group provides diagnostic solutions, including in-clinic and reference laboratory services, with a focus on integrated diagnostic information management through technologies like VetConnect PLUS[19][18]. - Livestock and poultry diagnostic products include tests for Bovine Viral Diarrhea Virus (BVDV) and Porcine Reproductive and Respiratory Syndrome (PRRS), aimed at improving producer efficiency and health management[44]. - Dairy products utilize the SNAP test platform to detect antibiotic drug residues in milk, with primary products including SNAP Beta-Lactam ST and SNAPduo Beta-Tetra ST[45]. - The company’s water testing products have received EPA approval for various regulatory programs, ensuring compliance with extensive regulatory processes[71]. Research and Development - Research and development expenses for the year ended December 31, 2022, were $254.8 million, representing 7.6% of consolidated revenue, compared to $161.0 million (5.0%) in 2021 and $141.2 million (5.2%) in 2020[53]. - The company maintains active research and development programs across all business segments, focusing on new product development and entry into new business areas[53]. - The company invests significantly in R&D to enhance existing products and develop new offerings, but there is no assurance of successful outcomes[116]. Regulatory Compliance - The company is subject to various U.S. and foreign regulatory authorities, including the FDA and EPA, impacting product development and marketing[79]. - Regulatory approvals for products are required in various jurisdictions, and delays in obtaining these approvals could negatively impact growth and profitability[108]. - Compliance with complex legal and regulatory requirements may lead to significant costs and operational challenges[114]. - The company maintains an active regulatory program to secure approvals in various countries, primarily in Europe, to support its water testing products[209]. Market Competition - The company competes with major players in the veterinary diagnostic market, including Antech Diagnostics, Zoetis Inc., and Heska Corporation, focusing on product quality and diagnostic accuracy[66]. - Increased competition in the veterinary diagnostic sector may negatively affect the company's operating results, especially with new entrants and consolidation among competitors[121]. - Competition may negatively impact sales and profitability due to new entrants and innovative products, potentially leading to obsolescence of existing offerings[122]. Financial Performance - Recurring diagnostic revenue accounted for approximately 79% of consolidated revenue for the year ended December 31, 2022[196]. - Revenues from IDEXX VetLab consumables and SNAP rapid assay test kits are considered recurring and have significantly higher gross margins than instrument sales[192]. - Approximately 35% of the company's overall revenue for the year ended December 31, 2022, was attributable to international sales, with 32%, 86%, and 51% of CAG, LPD, and Water revenues coming from outside the U.S. respectively[138]. Employee and Workforce Diversity - As of December 31, 2022, the company had approximately 10,780 regular full-time and part-time employees, with underrepresented minorities representing 23.7% of U.S. employees[82]. - Women represented 58% of the global employee population as of December 31, 2022, with 49.2% of global people managers identifying as women[84]. - The overall voluntary employee turnover rate was 13.3% in 2022, with managerial employee turnover at 6.6%[91]. - The company emphasizes the importance of diversity, equity, and inclusion (DEI) in its workforce to drive innovation and better serve its global customer base[81]. Supply Chain and Manufacturing - The company relies on third-party suppliers for components and raw materials, which could disrupt supply chains and negatively impact sales and profitability[101]. - The company purchases many products from sole or single sources, increasing vulnerability to supply disruptions and potential cost increases[104]. - The company’s manufacturing and distribution facilities are certified to ISO 9001 quality standards, ensuring compliance with international manufacturing standards[63]. Strategic Initiatives - The company aims to maintain premium pricing for its differentiated products and services, despite competition promoting lower-priced offerings[98]. - The company is focused on expanding its companion animal diagnostic sales and marketing organizations in both U.S. and international regions[98]. - The company is constructing a new facility in Scarborough, Maine, expected to be completed in 2023, to support growth in its Water and LPD lines of business[173]. Risks and Challenges - Long-term disruptions in supply chains could lead to permanent loss of customers, reducing recurring revenues and long-term profitability[106]. - Public health issues, including pandemics, could adversely affect operations and demand for products and services, leading to financial impacts[130]. - Cybersecurity threats pose risks to information systems, which could lead to operational disruptions and financial losses if breaches occur[132]. - The ongoing geopolitical tensions, particularly the war between Russia and Ukraine, could negatively impact international sales and operations[138]. Product Development and Innovation - The company differentiates its products based on time-to-result, ease-of-use, and superior customer service[195]. - The water testing business strategy focuses on developing products for microbial contamination detection, with growth dependent on increasing international sales and enhancing the product line[209]. - The livestock testing segment offers differentiated tests for disease management, including the Alertys Ruminant Pregnancy Test, which detects pregnancy 28 days post-breeding[210]. - The dairy testing strategy involves developing antibiotic residue and contaminant testing products that meet regulatory requirements, leveraging the SNAP platform for production[212].

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q4 2022 Results Conference Call February 6, 2023 8:30 AM ET Company Participants Jay Mazelsky - President and Chief Executive Officer Brian McKeon - Chief Financial Officer John Ravis - Vice President, Investor Relations Conference Call Participants Nathan Rich - Goldman Sachs Chris Schott - JPMorgan Erin Wright - Morgan Stanley Michael Ryskin - Bank of America Jon Block - Stifel Ryan Daniels - William Blair Operator Good morning, and welcome to the IDEXX Laboratories ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) One IDEXX Drive Westbrook Maine 04092 (Address of principal executive offices) (ZIP Code) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 ...

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Brian McKeon - CFO Jay Mazelsky - CEO Conference Call Participants Chris Schott - JPMorgan Erin Wright - Morgan Stanley Jon Block - Stifel Nathan Rich - Goldman Sachs David Westenberg - Piper Sandler Ryan Daniels - William Blair Elliot Wilbur - Raymond James Operator Good morning, and welcome to the IDEXX Laboratories Third Quarter 2022 Earnings Conference Call. As a reminder, today's ...

IDEXX Q3 2022 Earnings Highlights (NASDAQ: IDXX) Revenue Operating Profit Diluted Earnings Per Share +4% +6% +8% Reported growth: of Revenue Reported growth: Organic growth: YoY change in basis points: CAG Diagnostics Recurring Organic growth: Reported Comparable Comparable growth: +9% +120 bps +13% | --- | --- | --- | --- | --- | --- | --- | --- | --- | |---------------------------------------------------------------|-------------|----------------------------------|--------------------------------|-------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________. COMMISSION FILE NUMBER: 000-19271 Securities Registered pursuant to Section 12(b) of the Act: | Title of each class | Tradi ...

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q2 2022 Earnings Conference Call August 2, 2022 8:30 AM ET Company Participants Brian McKeon - Executive Vice President, Chief Financial Officer & Treasurer Jay Mazelsky - President & Chief Executive Officer Conference Call Participants Michael Ryskin - Bank of America Chris Schott - JPMorgan Erin Wright - Morgan Stanley Jon Block - Stifel Elliot Wilbur - Raymond James Ryan Daniels - William Blair Operator Good morning, and welcome to the IDEXX Laboratories Second Quar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________. COMMISSION FILE NUMBER: 000-19271 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) | Title ...

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Brian McKeon - CFO, EVP & Treasurer Jonathan Mazelsky - President, CEO & Director Conference Call Participants Christopher Schott - JPMorgan Chase & Co Michael Ryskin - Bank of America Merrill Lynch Erin Wright - Morgan Stanley Jonathan Block - Stifel, Nicolaus & Company Nathan Rich - Goldman Sachs Group Balaji Prasad - Barclays Bank Operator Good morning, and welcome to the IDEXX Laboratories ...